Vistagen Therapeutics, Inc. (VTGN): Nasdaq/NYSE listing notice — Vistagen gets 180-day Nasdaq extension to Sept 5, 2023 to regain $1 bid price compliance

Vistagen Therapeutics, Inc.

Company failed to meet $1.00 minimum bid price by March 6, 2023 deadline.
Nasdaq granted extension until September 5, 2023 to cure deficiency.
If not compliant by Sept 5, Nasdaq will initiate delisting; company may appeal.
No effect on current listing; trading continues on Nasdaq Capital Market.
Previously disclosed in September 2022 that bid price had been below $1 for 30 consecutive days.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.82

Vistagen Therapeutics, Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: compliance regained
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

September 5, 2023 (the “ Extension Period ”), to regain compliance with the requirement for the Company’s common stock, par value $0.001 per share (“ Common Stock ”), to maintain a minimum bid price of $1.00 per share for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “ Minimum Bid Price Requirement ”). The Extension Notice has no immediate effect on the continued listing status of the Company's Common Stock on the Nasdaq Capital Market. The Company's listing on the Nasdaq Capital Market remains fully effective. As previously disclosed in th

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Vistagen Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-005679

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.